Notably, SCLC subclones with highest ASNS retain superior resistance to asparaginase, mTOR inhibitors, and certain cytotoxicity, arguing for the importance of patient stratification by ASNS status in future clinical trials [9,36,48]. This evidence concerns the gene MTOR and small cell lung carcinoma.